Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)
Objective: To observe whether increasing the istradefylline dose from 20 to 40mg/day provides more patients with meaningful clinical responses. Background: Istradefylline, a well-tolerated selective adenosine…Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis
Objective: To evaluate the Levodopa induced dyskinesia (LID) in the clinical view point of autophagy and cellular energy homeostasis, and the pharmacological effect of adenosine…Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)
Objective: To evaluate the clinical effect of istradefylline as adjunctive treatment to LD in PD patients with or without additional PD medications (meds). Background: Istradefylline,…Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist
Objective: To evaluate whether an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A receptor antagonist preladenant prevent the onset of…The frequency of lower urinary tract symptoms in patients with Parkinson’s disease and Clinical efficacy of istradefylline
Objective: We evaluated using the questionnaire to investigate the frequency of lower urinary tract symptoms (LUTSs) in Parkinson's disease at our clinic. For patients with…Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…The complementary relationship between zonisamide and istradefylline in treating patients with Parkinson’s disease
Objective: To investigate patients with Parkinson’s disease (PD) who received zonisamide and istradefylline at the same period. Background: Zonisamide and istradefylline are anti-PD drugs with…Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease
Objective: In the present study, we intended to develop novel 1,2,4 triazole as potent A(2A)AR antagonists against parkinson’s disease. Background: Parkinson’s disease (PD) is a…Istradefylline improves motor symptoms in Parkinson’s disease: A meta-analysis
Objective: The aim of this meta-analysis was to provide strong evidence for the main and side effects of istradefylline on patients with Parkinson’s disease. Background:…Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.
Objective: This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…